Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young Saing | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Baek, Min Young | - |
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Lee, Woon Ki | - |
dc.contributor.author | Chung, Min | - |
dc.contributor.author | Kim, Hyung-Sik | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.date.available | 2020-02-28T07:41:56Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-12 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/9871 | - |
dc.description.abstract | Single-agent chemotherapy is considered a good and safe treatment option for elderly patients with advanced gastric cancer (AGC). We investigated the efficacy and safety of trastuzumab plus low-dose capecitabine in elderly patients with previously untreated human epidermal growth factor receptor 2 (HER2)-positive AGC. Patients aged 75 years or older with tumors having HER2 overexpression defined as either immunohistochemistry (IHC) 3+ or IHC 2+ and in situ hybridization-positive were eligible for inclusion. Patients received capecitabine (1000 mg/m(2)) orally twice daily on days 1-14 and trastuzumab (8 mg/kg for cycle 1, followed by 6 mg/kg) intravenously on day 1 of a 21-day cycle. The primary endpoint was progression-free survival (PFS). Twenty patients were enrolled. The median age was 79 years (range 75-91). Nine patients (45 %) had ECOG performance status 2. Median PFS was 5.2 months (95 % CI 1.9-8.4 months), and median overall survival was 9.3 months (95 % CI 4.0-14.6 months). The confirmed response rate was 40 % (95 % CI 19-64 %) with disease control rate of 80 %. Grade 3-4 toxicities were anorexia (10 %), fatigue (5 %), stomatitis (5 %), and anemia (5 %). No treatment-related deaths or symptomatic congestive heart failure were observed. Low-dose capecitabine plus trastuzumab is effective and well tolerated in elderly patients with HER2-positive AGC. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.subject | MULTICENTER PHASE-II | - |
dc.subject | TRIAL | - |
dc.subject | STATISTICS | - |
dc.title | Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000365217800017 | - |
dc.identifier.doi | 10.1007/s00280-015-2881-x | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.76, no.6, pp.1267 - 1272 | - |
dc.identifier.scopusid | 2-s2.0-84947554532 | - |
dc.citation.endPage | 1272 | - |
dc.citation.startPage | 1267 | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 76 | - |
dc.citation.number | 6 | - |
dc.contributor.affiliatedAuthor | Kim, Young Saing | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.contributor.affiliatedAuthor | Baek, Min Young | - |
dc.contributor.affiliatedAuthor | Park, Inkeun | - |
dc.contributor.affiliatedAuthor | Hong, Junshik | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Park, Jinny | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.contributor.affiliatedAuthor | Lee, Woon Ki | - |
dc.contributor.affiliatedAuthor | Chung, Min | - |
dc.contributor.affiliatedAuthor | Kim, Hyung-Sik | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Shin, Dong Bok | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | HER2 | - |
dc.subject.keywordAuthor | Trastuzumab | - |
dc.subject.keywordAuthor | Capecitabine | - |
dc.subject.keywordAuthor | Elderly | - |
dc.subject.keywordPlus | MULTICENTER PHASE-II | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | STATISTICS | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.